The Inquiry cover image

Are weight loss drugs the answer to obesity?

The Inquiry

00:00

The Future of Weight Loss Drugs

Novo's patent for Simaglitide is due to expire in 2030. It could try to extend that, which would give it another five years. But what happens thereafter is that they go generic, meaning anybody else can produce the substance and sell it. So many, many people will get access to the drug to a lower price. And I think this is something very wonderful in the long run. There are major improvements to be done on the patient but also on the economics.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app